Formulation Development
Salubris Biotherapeutics Announces $35 Million in Financing & Provides Pipeline Progress Update
Salubris Biotherapeutics, Inc. recently announced a new capital infusion of $35 million to fund continued research and development of clinical and preclinical programs. SalubrisBio also…
Cellares & Bristol Myers Squibb Announce $380-M Worldwide Capacity Reservation & Supply Agreement
Cellares, the world’s first Integrated Development and Manufacturing Organization (IDMO), will allocate multiple Cell Shuttles and its fully automated, high-throughput Cell Q systems across its IDMO Smart Factories in the US, EU, and Japan for Bristol Myers Squibb’s use ….
Neurolentech Signs Technology Access Partnership With Kaerus Bioscience
Kaerus Bioscience will access Neurolentech’s NDD Drug Discovery Platform to support development of its preclinical asset pipeline for numerous genetic syndromes….
Nutcracker Therapeutics Demonstrates Positive Data on Anti-Prostate Cancer Therapeutic
Nutcracker Therapeutics, Inc. recently presented two posters at the American Association for Cancer Research (AACR) Annual Meeting in San Diego: one showcasing the latest preclinical data…
Regeneration Biomedical Doses First Patient in a First-in-Human Phase 1 Clinical Trial of Stem Cell Therapy Delivered Directly Into the Brain of Patients With Alzheimer’s Disease
Regeneration Biomedical, Inc. recently announced the first patient has been dosed in an FDA-cleared, first-in-human Phase 1 clinical trial of autologous, Wnt-Activated Adipose-Derived Stem Cells…
Lisata Therapeutics & Qilu Pharmaceutical Announce First Patient Treated in Qilu’s Phase 2 Trial
Lisata Therapeutics, Inc. and Qilu Pharmaceutical Co., Ltd. recently announced the first patient has been treated in Qilu’s Phase 2 trial in China evaluating LSTA1…
Wave Life Sciences Announces Continued Momentum in GSK Collaboration & Advancements in siRNA & RNA Editing
Wave Life Sciences Ltd. recently provided an update on its best-in-class small interfering RNA (siRNA) and RNA editing platform capabilities. As part of Wave’s ongoing…
Palisade Bio Enters Strategic Collaboration With Strand Life Sciences to Advance Precision Medicine Approach
Partnership marks a significant value-driving milestone in Palisade Bio’s mission to redefine UC treatment through targeted interventions based on PDE4-related biomarkers….
Petros Pharmaceuticals Receives Positive Response from FDA Following Recent Demonstration of Technology Component in Pursuit of OTC Status for STENDRA
Petros Pharmaceuticals, Inc. recently announces it has received positive feedback from the US FDA following the FDA’s informal review of Petros’ technology component for self-selection…
CordenPharma & GENEPEP Celebrate Strong Collaboration Leveraging Peptide Drug Substance Discovery & Clinical Development Expertise
CordenPharma and GENEPEP have recently celebrated 1 year of their fruitful partnership signed in 2023, which supports biotech companies with the development, discovery, and manufacturing…
Evaxion Announces Phase 2 Clinical Trial Update: First Patient Completed Dosing With Personalized Cancer Vaccine
Significant Phase 2 clinical trial progress obtained with first patient finalizing EVX-01 vaccine dosing….
Atossa Therapeutics & Quantum Leap Healthcare Announce Clinical Trial to Evaluate (Z)-Endoxifen in Combination With Abemaciclib in Women With ER+/HER2- Breast Cancer
Atossa Therapeutics, Inc. and Quantum Leap Healthcare Collaborative recently announced the initiation of a new study to evaluate Atossa’s proprietary (Z)-endoxifen in combination with abemaciclib…
Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration With Neurocrine Biosciences, Triggering Milestone Payment
Voyager Therapeutics, Inc. recently announced the joint steering committee with its collaborator Neurocrine Biosciences has selected a lead development candidate in the GBA1 gene therapy program for the potential treatment of Parkinson’s disease….
Kincell Bio & Imugene Announce Strategic Manufacturing & Process Development Partnership
Kincell Bio to acquire Imugene’s North Carolina manufacturing facility for up to $6M USD in upfront and milestone-driven payments over 3 years….
Cullinan Therapeutics Announces Strategic Expansion Into Autoimmune Diseases & $280-Million Private Placement
CLN-978 clinical development to focus exclusively on autoimmune diseases, pursuing systemic lupus erythematosus as a first indication….
SAB Biotherapeutics Provides SAB-142 Trial Update
SAB Biotherapeutics, Inc. recently announced its Chief Medical Officer, Dr. Alexandra Kropotova, MD, MBA, disclosed SAB has completed dosing the third cohort for SAB-142 with…
GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T Cell Modulators With Issuance of Patent
GRI Bio, Inc. recently announced the Korean Intellectual Property Office (KIPO) has issued a Notice of Patent Grant for Patent Application No. 10-2017-7018579 titled Prevention…
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis
Organovo Holdings, Inc. recently released the complete details of its 16-week, randomized, placebo-controlled, multi-center Phase 2 study of the non-steroidal, non-bile acid FXR agonist FXR314…
Cresset Creates New Vice President Role to Lead its Artificial Intelligence Strategy
Cresset an innovative provider of solutions for CADD, DMTA efficiency, and contract research, has expanded its senior leadership team with the appointment of Cambridge Scientist…
BC Platforms & NTT Group Announce Official Opening Ceremony for Exclusive Collaboration & Launch of Japanese Precision Medicine Platform
BC Platforms (BCP) recently announces an exclusive collaboration with NTT Life Science Corporation, a company in the medical field of the NTT Group, to accelerate data-driven….
